Page 51 - Amgen News Today

Horan Capital Advisors LLC. reduced its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 4.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,334 shares of the medical research company’s stock after selling 604 shares during the […]

Amgen (NASDAQ:AMGN – Get Free Report) posted its earnings results on Thursday. The medical research company reported $3.96 earnings per share for the quarter, topping analysts’ consensus estimates of $3.76 by $0.20, Briefing.com reports. The business had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.45 billion. Amgen had a return […]

Stocks closed sharply higher on Wall Street, erasing their losses for the week, after the government reported a cooldown in hiring last month. For markets that was a welcome sign

StockNews.com upgraded shares of Amgen (NASDAQ:AMGN – Free Report) from a hold rating to a buy rating in a research note published on Friday. A number of other analysts have also recently issued reports on AMGN. William Blair raised Amgen from a market perform rating to an outperform rating in a report on Friday. Raymond […]

Goldman Sachs said Amgen's experimental GLP-1 drug could have peak sales of $5 billion, or 5% of the estimated $100 billion weight loss drug market.

Stocks in Toronto gained strength by the end of the Thursday session, following up on the good vibes given off by Bank of Canada Tiff Macklem that interest rates are not likely to jump any time soon. The TSX Composite recovered 94.67 points to ...

Benjamin F. Edwards & Company Inc. boosted its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 14.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 35,422 shares of the medical research company’s stock after acquiring an additional 4,440 shares during the […]

Amgen (NASDAQ:AMGN – Get Free Report) posted its earnings results on Thursday. The medical research company reported $3.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.76 by $0.20, Briefing.com reports. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The business had revenue of $7.45 […]

Wall Street capped a choppy week of trading Friday with the best day for the stock market in over two months, as traders welcomed cooler-than-expected U.S. employment data as a sign that inflationary pressures on the economy are easing.

Amgen (NASDAQ:AMGN – Free Report) had its price objective upped by UBS Group from $284.00 to $307.00 in a research report report published on Friday morning, Benzinga reports. UBS Group currently has a neutral rating on the medical research company’s stock. A number of other analysts also recently issued reports on the stock. Truist Financial […]